pharma news today glp-1 obesity drug Federal regulators on Wednesday approved Eli Lilly's new weight-loss pill, a second daily oral medication to treat and other weight-related conditions Could weight-loss drugs eat the

American Association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity

Its important to understand that for Wegovy, only the marked doses on the single-use, fixed-dose pens are approved for use and represent an authentic FDA-approved medicine. Eli Lilly says it doesnt have any data on the benefits or risks of microdosing tirzepatide, the active ingredient in Zepbound and Mounjaro

Providers who submit PAs regularly learn to include the magic phrases: "failed 6-month medically supervised weight loss program," "documented BMI 32 with hypertension and prediabetes," "requesting Wegovy for treatment of obesity-related comorbidities." The coverage difference between Wegovy, Ozempic, and compounded semaglutide All three contain semaglutide, but Ambetter treats them as separate drugs with separate coverage rules: The loophole many patients attempt: ask the provider to prescribe Ozempic off-label for weight loss

Moving Forward If you're considering a GLP-1 medication, here's what you need to know in plain terms: Buying these medications online without a prescription is not safe Taking them without proper screening means you may not know if they're safe for you Managing dosing on your own significantly increases your risk of side effects and poor results Without nutritional guidance, you may lose muscle instead of fat Long-term success requires more than a prescription

Researchers say it helps people with obesity lose meaningful weight and improve blood sugar levels without the hurdles of injectable drugs

The Rise of GLP-1 Receptor Agonists in Australia & AI's Transformative Role The Australian market for GLP-1 receptor agonists is poised for substantial expansion, driven by the increasing prevalence of type 2 diabetes and obesity